FAP-targeted radionuclide therapy with [<superscript>177</superscript>Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma.
In: European Journal of Nuclear Medicine & Molecular Imaging, Jg. 49 (2022-04-01), Heft 5, S. 1767-1769
Online
academicJournal
Zugriff:
The article describes the case of a 25-year-old man who was diagnosed with non-keratinizing undifferentiated nasopharyngeal carcinoma (T2N3M0) in July 2019. Topics covered include the medical history of the patient, patient outcome after receiving the experimental therapy, fibroblast activation protein (FAP)-targeted radionuclide therapy, and the potential feasibility of FAPI-46 in the treatment of metastatic nasopharyngeal carcinoma as demonstrated by the case.
Titel: |
FAP-targeted radionuclide therapy with [<superscript>177</superscript>Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma.
|
---|---|
Autor/in / Beteiligte Person: | Fu, Kaili ; Pang, Yizhen ; Zhao, Liang ; Lin, Limei ; Wu, Hua ; Sun, Long ; Lin, Qin ; Chen, Haojun |
Link: | |
Zeitschrift: | European Journal of Nuclear Medicine & Molecular Imaging, Jg. 49 (2022-04-01), Heft 5, S. 1767-1769 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 1619-7070 (print) |
DOI: | 10.1007/s00259-021-05634-3 |
Schlagwort: |
|
Sonstiges: |
|